INS and hypogonadism: A recent double‐blind placebo‐controlled trial of testosterone treatment in 788 older men showed no impact on serum glucose or HbA1C34; another study showed no change in insulin sensitivity after 36 months of treatment in 308 community‐dwelling men.35 The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy in men with hypogonadism no longer recommend screening men with T2DM for low serum testosterone, and advise against using testosterone therapy to improve glycaemic control.36